Glaukos (NYSE:GKOS) Stock Price Expected to Rise, BTIG Research Analyst Says

Glaukos (NYSE:GKOS) had its target price increased by BTIG Research from $164.00 to $193.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s target price indicates a potential upside of 15.90% from the stock’s current price.

A number of other analysts have also recently commented on the company. Wells Fargo & Company upped their price target on Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a research note on Thursday. Stifel Nicolaus boosted their price objective on shares of Glaukos from $170.00 to $175.00 and gave the company a “buy” rating in a report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 target price on shares of Glaukos in a research note on Wednesday, July 1st. Truist Financial upped their target price on shares of Glaukos from $180.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Needham & Company LLC increased their target price on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $177.33.

Glaukos Stock Down 1.2%

Shares of Glaukos stock opened at $166.52 on Thursday. The company has a quick ratio of 4.73, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. Glaukos has a 12 month low of $73.16 and a 12 month high of $184.00. The business has a fifty day simple moving average of $138.11 and a 200 day simple moving average of $125.07. The stock has a market cap of $9.78 billion, a PE ratio of -51.24 and a beta of 0.75.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same quarter in the prior year, the firm posted ($0.24) earnings per share. The company’s quarterly revenue was up 49.6% on a year-over-year basis. Research analysts predict that Glaukos will post -0.57 EPS for the current year.

Insider Activity

In related news, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 16th. The stock was sold at an average price of $160.00, for a total value of $1,600,000.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at approximately $7,024,960. The trade was a 18.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the sale, the director directly owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. The trade was a 12.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 40,000 shares of company stock worth $6,028,800 in the last quarter. 5.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Glaukos

Large investors have recently made changes to their positions in the stock. Stephens Inc. AR acquired a new position in Glaukos in the 1st quarter worth $363,000. Allspring Global Investments Holdings LLC increased its holdings in Glaukos by 32.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock worth $39,336,000 after purchasing an additional 87,781 shares in the last quarter. Capricorn Fund Managers Ltd acquired a new stake in shares of Glaukos in the 4th quarter valued at about $6,775,000. DNB Asset Management AS raised its stake in shares of Glaukos by 11.9% in the 4th quarter. DNB Asset Management AS now owns 82,320 shares of the medical instruments supplier’s stock valued at $9,295,000 after purchasing an additional 8,770 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Glaukos by 209.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock valued at $152,476,000 after purchasing an additional 913,458 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Quarterly results exceeded expectations. Glaukos reported second-quarter revenue of $185.6 million, up 49.6% year over year and well above the $150.9 million consensus estimate. Its adjusted loss of $0.14 per share was narrower than the expected $0.21 loss, supported by growth in iDose TR and Epioxa. Glaukos Q2 Earnings Beat Estimates on iDose TR Growth
• Positive Sentiment: Management raised its 2026 outlook. Glaukos now expects net sales of $680 million to $700 million, with iDose TR revenue projected at $275 million to $280 million. The higher forecast signals continued commercial momentum and was a key reason the stock advanced. Glaukos outlines 2026 sales outlook
• Positive Sentiment: Clinical and analyst catalysts added support. The company reported progress on its PRESERFLO study, while BTIG raised its price target from $164 to $193 and maintained a Buy rating. BTIG raises Glaukos price target
• Neutral Sentiment: UBS Group initiated coverage of Glaukos, potentially broadening institutional attention, although the available report does not provide a detailed rating or price target. UBS initiates Glaukos coverage
• Negative Sentiment: Valuation and profitability remain risks. Despite the improved results, Glaukos remains unprofitable, and commentary questioned whether the stock’s strong rally has priced in much of its growth potential. Future gains may depend on continued iDose TR adoption and execution against the raised forecast. Glaukos record sales and valuation analysis

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.